Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Norland's X-ray device will assess fracture risk:

This article was originally published in Clinica

Executive Summary

Norland Medical Systems has received 510(k) clearance from the FDA to market a fracture risk assessment feature on its Apollo DXA peripheral bone densitometer. Until recently, doctors could not easily predict which osteoporosis sufferers were at high risk of a bone fracture, but last year the FDA determined that manufacturers of bone density devices could offer a feature which would help. This feature is already available on Norland's pDEXA device.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT081654

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel